PW Medtech Group Co. Ltd. has announced a voluntary share repurchase under the Repurchase Mandate. The company has the authorization to repurchase up to 10% of its total shares in issue, excluding treasury shares, up to 148,673,509 shares, as approved during the annual general meeting on June 10, 2025. The repurchase will be subject to market conditions and determined at the Board's discretion, with no assurance on timing, quantity, or price. The repurchase will be financed from the company's existing available cash.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.